By Randi Kahn
We often tell clients to closely monitor their environment and get ahead of issues. As such, we wanted to share an example of a company who did just that this week.
As news broke of nineteen women filing a lawsuit against Lyft alleging the company had not done enough to address sexual assaults, Uber released a safety report with some shocking figures (e.g., 3,000+ reports of sexual assaults during rides in the US in 2018). Uber has been criticized for its safety in the past. But there are lessons in the company’s proactivity in sharing negative data and the timeliness of the safety report.
Uber acknowledged an industry-wide problem and provided concrete plans for dealing with the issue. It extended and broadened categories of assault beyond legal definitions, garnering support from major advocacy organizations. And it developed benchmarks where there were none, taking a leadership position. Additionally, the company announced partnerships with notable victim support groups and groups dedicated to awareness and prevention of sexual violence, showing further dedication to addressing the issue of sexual assault in ride shares.
Putting out a report like this was risky—and Uber did get some negative headlines—but the strategy worked. Their stock didn’t see a marked decline and overall, the news coverage, once you read past the headlines, was balanced. Leveraging good PR tactics yielded bridges built with advocacy organizations and balance and context included in the full news stories. Plus, by setting benchmarks for the industry, the company set itself up as an industry leader and led to calls for competitors to release their own safety data. This is quite a reputation change from the days leading up to #MeToo.
“Confronting sexual violence requires honesty, and it’s only by shining a light on these issues that we can begin to provide clarity on something that touches every corner of society,” the company’s chief legal officer, Tony West, said in the executive summary of the report. “The moment is now for companies to confront it, count it, and work together to end it.”
Now that’s leadership.
Drug regulators and developers are rapidly expanding the use of real-world evidence (RWE) in the evaluation of rare therapies, but a new report from Syneos Health shows that payers are lagging behind in adopting RWE and are skeptical of its value.
RRM’s fearless leader, Meg Alexander, spoke to Danny Levine on Global Genes’ RAREDaily podcast about the areas where RWE has played an important role in transforming drug development --from showing us how medicines work outside of clinical trials, to expediting drug approvals and helping patients gain affordable access to their medications. She also details how different countries are using RWE data.
Check it out!
Who wrote this? The managing editor of TWTW is Randi Kahn, who is excited to pick out her first Christmas tree this weekend. Happy almost holidays, everyone! Syneos Health Communications' Reputation & Risk Management Practice is a team of healthcare communications consultants, policy-shapers and crisis response specialists. We provide unique solutions to the evolving communications challenges in today’s healthcare industry, using evidence-based approaches to help our clients successfully navigate the most sensitive of situations.
Got thoughts? Contact Randi
Did someone forward this to you? You’re so lucky! Sign up to receive TWTW every week.
Feeling nostalgic? We get it. Check out old TWTW issues here.
Want to find us? 200 Vesey St., New York, NY 10285